ALDEYRA THERAPEUTICS
Aldeyra Therapeutics is a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's lead investigational drug product candidates are first-in-class potential treatments in development for dry eye disease, allergic conjunctivitis, proliferative vitreoretinopathy, and Sjögren-Larsson Syndrome. The company is also developing other product candidates for retinal and systemic inflammatory diseases.
ALDEYRA THERAPEUTICS
Industry:
Biotechnology Developer Platform Health Care Therapeutics
Founded:
2004-01-01
Address:
Burlington, Massachusetts, United States
Country:
United States
Website Url:
http://www.aldeyra.com
Total Employee:
11+
Status:
Active
Contact:
(646) 536-7009
Email Addresses:
[email protected]
Total Funding:
287.39 M USD
Technology used in webpage:
IPv6 Gravity Forms DigiCert SSL Akamai Hosted RapidSSL IHS Markit
Similar Organizations
Akebia Therapeutics
Akebia Therapeutics develops treatments for ischemia and vascular diseases.
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2019-01-29 | Helio Vision | Helio Vision acquired by Aldeyra Therapeutics | 25 M USD |
Investors List
Hercules Capital
Hercules Capital investment in Post-IPO Debt - Aldeyra Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2022-04-28 | Aldeyra Therapeutics Announces Chief Financial Officer Transition |
Official Site Inspections
http://www.aldeyra.com Semrush global rank: 7.49 M Semrush visits lastest month: 758
- Host name: 42.57.196.35.bc.googleusercontent.com
- IP address: 35.196.57.42
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Aldeyra Therapeutics"
Aldeyra Therapeutics - Crunchbase Company Profile & Funding
Aldeyra Therapeutics is a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. …See details»
Leadership | Aldeyra Therapeutics Inc.
Dr. Bronstein joined the Aldeyra board of directors in 2010, and is an independent consultant to companies in the life science industry. Prior to his consulting role, he was Executive Vice …See details»
Investor Relations | Aldeyra Therapeutics, Inc.
Feb 11, 2025 Aldeyra develops innovative therapies designed to treat immune-mediated diseases. Our approach is to discover pharmaceuticals that modulate immunological systems, …See details»
Aldeyra Therapeutics (ALDX) Company Profile & Description
May 2, 2014 Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases. Its lead product …See details»
Press Releases - Aldeyra Therapeutics, Inc.
Mar 10, 2025 LEXINGTON, Mass. --(BUSINESS WIRE)--May 5, 2025-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on …See details»
Aldeyra Therapeutics - Org Chart, Teams, Culture & Jobs - The Org
View Aldeyra Therapeutics' up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more. This is an unverified company page.See details»
Aldeyra Therapeutics, Inc. (ALDX): history, ownership, mission, how …
Aldeyra Therapeutics, Inc.'s Current Status As of the end of 2024, Aldeyra Therapeutics, Inc. is a publicly listed company, trading under the ticker symbol ALDX on the Nasdaq stock exchange. …See details»
Aldeyra Therapeutics, Inc. - VentureRadar
At Aldeyra, we’re a pioneer in the development of medicines to improve the lives of patients with immune-mediated diseases. Our pipeline of drug candidates is focused on inhibiting …See details»
ALDEYRA THERAPEUTICS, INC.
ALDEYRA THERAPEUTICS, INC. (E xac t name of Re gi s tr ant as Spe c i fi e d i n I ts Char te r ) De l awar e. 20-1968197 (State or O the r Jur i s di c ti on. of I nc or por ati on or O r gani z …See details»
Aldeyra Therapeutics - Craft
Oct 29, 2024 Aldeyra Therapeutics is a biotechnology company focused primarily on the development of new products for immune-mediated, inflammatory, orphan and other diseases …See details»
About Aldeyra Therapeutics | Aldeyra Pharmaceuticals, Inc.
Aldeyra’s Mission At Aldeyra, we are devoted to developing medications to enhance the well-being of patients dealing with immune-mediated and metabolic illnesses. Our portfolio of …See details»
Aldeyra Therapeutics Schedules Conference Call and Webcast to …
4 days ago LEXINGTON, Mass., May 05, 2025--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Tuesday, May 6, …See details»
ALDX SECURITIES UPDATE: Aldeyra Therapeutics Investors
2 days ago This news caused the price of Aldeyra Therapeutics stock to fall nearly 75% over the course of the trading day, from a closing price of $5.33 per share on April 2, 2025.See details»
Understanding the Latest Developments at Aldeyra Therapeutics
Dec 26, 2024 This implies that Aldeyra’s products have successfully passed through rigorous clinical trials and are on the verge of being made available to the public. This turning point is a …See details»
Aldeyra Therapeutics Receives Complete Response Letter from the …
Apr 3, 2025 LEXINGTON, Mass.--(BUSINESS WIRE)--Apr. 3, 2025-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing …See details»
Pipeline + Disease Areas | Aldeyra Therapeutics Inc.
Aldeyra is a well-capitalized biotechnology company with a broad pipeline focused on immune-mediated and metabolic disease. Reproxalap Topical ocular administrationSee details»
Aldeyra’s dry eye drug suffers second FDA rejection, but imminent …
Apr 3, 2025 Aldeyra first filed for FDA approval of reproxalap, a small molecule that binds reactive aldehyde species, in 2022. The company included data from two trials for ocular …See details»
Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry …
3 days ago Aldeyra Therapeutics, Inc., a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, …See details»
Aldeyra’s Surprising Turnaround: What Lies Ahead?
Apr 3, 2025 Aldeyra Therapeutics Inc.’s stocks, trading down -72.39%, could face further pressure following recent unfavorable news articles. Key Developments Shaping the ALDX …See details»
Aldeyra makes third run at FDA approval for dry eye drug
2 days ago Aldeyra said there were no major differences between the two treatment arms at the start of the trial, a factor that had previously raised concerns with US regulators. The company …See details»